Toxic epidermal necrolysis (TEN) is a severe cutaneous adverse drug reaction leading to extensive sloughing of the skin. Late cutaneous complications such as pigmentation disorders are frequently reported. In this report, we present particular facial cutaneous sequelae with histological analysis after TEN. Two young patients who had survived TEN presented permanent multiple hypopigmented papules on the face affecting their quality of life. Histological analysis revealed areas of scarring, dystrophic microcalcifications and sebaceous hyperplasia. Late cutaneous sequelae are well documented; however, the physiopathological mechanisms leading to different clinical presentations remain unknown. We suggest that the destruction of the hair follicle by necrolysis leads to secondary dermal microcalcifications, scarring and sebaceous hyperplasia. Further studies are needed for a better understanding of these findings.

Keywords:
Sebaceous hyperplasia, Fibrosis, Dystrophic calcification, Sequelae, Toxic epidermal necrolysis
1.
Harr T, French LE: Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39.
2.
Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al: Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013;133:1197-1204.
3.
De Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, Van Nhieu JT, Duong TA, Chosidow O, Wolkenstein P, Brun-Buisson C, Maître B: Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014;42:118-128.
4.
Haber J, Hopman W, Gomez M, Cartotto R: Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005;26:33-41.
5.
Schwartz RA, McDonough PH, Lee BW: Toxic epidermal necrolysis. II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013;69:187.e1-e16.
6.
Quirke KP, Beck A, Gamelli RL, Mosier MJ: A 15-year review of pediatric toxic epidermal necrolysis. J Burn Care Res 2015;36:130-136.
7.
Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimarães J: Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 2003;207:33-36.
8.
Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F, et al: Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol 2010;35:853-862.
9.
Ruiz-Maldonado R: Acute disseminated epidermal necrolysis types 1, 2 and 3: study of 60 cases. J Am Acad Dermatol 1985;13:623-635.
10.
Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, et al: Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005;85:497-502.
11.
Kreft B, Lieser U, Haase R, Marsch WC, Wohlrab J: Extensive hypertrophic scarring after toxic epidermal necrolysis in a child. Pediatr Dermatol 2014;31:527-528.
12.
Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E: Calcinosis cutis. I. Diagnostic pathway. J Am Acad Dermatol 2011;65:1-12; quiz 13-14.
13.
Walsh JS, Fairley JA: Calcifying disorders of the skin. J Am Acad Dermatol 1995;33:693-706.
14.
Rowan MP, Cancio LC, Elster EA, Burmeister DM, Rose LF, Natesan S, Chan RK, Christy RJ, Chung KK: Burn wound healing and treatment: review and advancements. Crit Care 2015;19:243.
15.
Valeyrie-Allanore L, Bastuji-Garin S, Guégan S, Ortonne N, Bagot M, Roujeau JC, Revuz JE, Wechsler J, Wolkenstein P: Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol 2013;68:e29-e35.
16.
Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, Ferron SR, Herault Y, Pavlovic G, Ferguson-Smith AC, Watt FM: Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 2013;504:277-281.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.